Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure

被引:21
|
作者
Huang, Dong-Hui [1 ]
Sun, Hao [1 ]
Shi, Jing-Pu [1 ]
机构
[1] China Med Univ, Dept Clin Epidemiol & Evidence Based Med, Inst Cardiovasc Dis, Hosp 1, Shenyang 110001, Liaoning, Peoples R China
关键词
Biomarker; Diagnosis; Heart Failure; Meta-analysis; Soluble Suppression of Tumorigenicity-2; RECEPTOR FAMILY-MEMBER; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE; EJECTION FRACTION; PROGNOSTIC UTILITY; ACUTE DYSPNEA; ST2; BIOMARKERS; ASSOCIATION; GALECTIN-3;
D O I
10.4103/0366-6999.177000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Many studies have explored the diagnostic performance of soluble suppression of tumorigenicity-2 (sST2) for heart failure (HF), but the results are inconsistent. Here, we performed a meta-analysis to assess the role of sST2 in the diagnosis of HF. Methods: We searched PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database from inception to April 2015. Studies that investigated the diagnostic role of sST2 for HF were reviewed. The numbers of true-positive, false-positive, false-negative, and true-negative results were extracted to calculate pooled diagnostic odds ratio (DOR) with 95% confidence interval (CI) and the summary receiver operating characteristic curve and area under the curve (AUC). The Spearman correlation coefficient was used to check the threshold effect. The Cochran Q statistic (P < 0.05) and the inconsistency index (I-2 > 50%) were used to assess the nonthreshold effect. Meta-regression was conducted to explore the source of heterogeneity; subgroup analysis showed the results in different subgroups. Finally, the Deeks' test was performed to assess the publication bias. Results: Nine articles including 10 studies were included in the meta-analysis. The pooled sensitivity was 0.84 (95% CI: 0.81-0.86), and pooled specificity was 0.74 (95% CI: 0.72-0.76). The summary DOR was 8.49 (95% CI: 4.54-15.86), and AUC was 0.81 (standard error: 0.03). The Spearman correlation coefficient identified the nonsignificant threshold effect (coefficient = 0.49, P = 0.148), but the nonthreshold effect heterogeneity was significant (Cochran Q = 58.52, P < 0.0001; I-2 = 84.6%). Meta-regression found that characteristics of controls might be the suggestive source of nonthreshold effect heterogeneity (P = 0.095). Subgroup analysis found that DOR was 5.65 and 7.86, respectively for the controls of hospital patients and healthy populations. Deeks' test demonstrated that there was no publication bias (P = 0.616). Conclusion: The meta-analysis illustrated that sST2 might play a role in diagnosing HF.
引用
收藏
页码:570 / 577
页数:8
相关论文
共 50 条
  • [41] Correlation Between Level of Soluble Suppression of Tumorigenicity-2 And Left Ventricle End-Diastolic Pressure In Acute Myocardial Infarction
    Kusumastuti, Dyah A.
    Taufiq, Nahar
    Mumpuni, Hasanah
    Hartopo, Anggoro B.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0F) : F50 - F50
  • [42] IL-33 (Interleukin 33)/sST2 (Soluble Suppression of Tumorigenicity 2) Axis in Hypertension and Heart Failure
    Ghali, Rana
    Altara, Raffaele
    Louch, William E.
    Cataliotti, Alessandro
    Mallat, Ziad
    Kaplan, Abdullah
    Zouein, Fouad A.
    Booz, George W.
    HYPERTENSION, 2018, 72 (04) : 818 - 828
  • [43] The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis
    Yang, Chaojun
    Fan, Zhixing
    Wu, Jinchun
    Zhang, Jing
    Zhang, Wei
    Yang, Jian
    Yang, Jun
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [44] Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
    Yang, Hyun Suk
    Hur, Mina
    Kim, Hanah
    Magrini, Laura
    Marino, Rossella
    Di Somma, Salvatore
    ANNALS OF LABORATORY MEDICINE, 2016, 36 (06) : 590 - 594
  • [45] Poststroke depression and soluble suppression of tumorigenicity 2
    Peng, Meidi
    Gong, Yachi
    Huang, Hongtao
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (07) : E52 - E52
  • [46] Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
    Zhang, Yunyun
    Xu, Qijiang
    Wu, Xiaofang
    Pu, Li
    Zang, Zhiyun
    Xia, Xiaoxiao
    Ma, Niya
    Li, Zi
    KIDNEY & BLOOD PRESSURE RESEARCH, 2024, 49 (01): : 726 - 734
  • [47] Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure-A Prospective Observational Study
    Dworok, Victoria
    Haehnel, Valentin
    Bannehr, Marwin
    Paar, Vera
    Edlinger, Christoph
    Lichtenauer, Michael
    Butter, Christian
    Haase-Fielitz, Anja
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [48] Correlation between Levels of Serum Lipoprotein-Associated Phospholipase A2 and Soluble Suppression of Tumorigenicity 2 and Condition of Acute Heart Failure Patients and Their Predictive Value for Prognosis
    Zhang, Jinjin
    Wang, Lei
    Zhao, Zhikun
    Li, Liang
    Xia, Yunfeng
    JOURNAL OF HEALTHCARE ENGINEERING, 2021, 2021
  • [49] The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis
    Liu, Niannian
    Hang, Tao
    Gao, Xiang
    Yang, Wenxue
    Kong, Wenjie
    Lou, Qiaozhen
    Yang, Jiming
    PLOS ONE, 2020, 15 (09):
  • [50] Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide
    Jin, Xiao-Ling
    Huang, Ning
    Shang, Hui
    Zhou, Ming-Cheng
    Hong, Yi
    Cai, Wen-Zheng
    Huang, Jie
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (03)